Literature DB >> 25239925

Antiphospholipid (Hughes) syndrome: description of population and health-related quality of life (HRQoL) using the SF-36.

S Georgopoulou1, S Efraimidou2, S J MacLennan3, F Ibrahim4, T Cox2.   

Abstract

OBJECTIVE: Antiphospholipid (Hughes) syndrome (APS) affects mainly women 15 to 50 years of age and is responsible for approximately 20% of strokes in people <40 years. Little is known about the psychological burden of this long-term condition. We investigated HRQoL in APS.
METHODS: We conducted a cross-sectional survey involving 270 members of the Hughes Syndrome Foundation worldwide. Data included HRQoL (SF-36), demographics, and APS-related self-reported major issues. Response rate was 60%.
RESULTS: T-tests indicated significantly worse mean scores for seven of the eight domains of the SF-36 in secondary antiphospholipid syndrome (SAPS) compared to primary antiphospholipid syndrome (PAPS), e.g. bodily pain t(263) = 6.10 p < 0.001 except for mental health t(267) = 1.95 p = 0.053. PAPS appeared to be associated with poorer HRQoL in most mental health domains but overall better physical domains compared to systemic lupus erythematosus (SLE) alone. SAPS appeared to have a more adverse impact on HRQoL compared to PAPS and SLE. Major issues identified: pain and fatigue, lack of health care professional/public awareness, and medication unpredictability.
CONCLUSION: HRQoL in PAPS appears to be generally better than SLE and SAPS in physical domains, but poorer in mental domains. APS patients might need more social support in terms of information and awareness of the condition to improve their coping strategies.
© The Author(s) 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  Antiphospholipid (Hughes) syndrome (APS); demographics; health-related quality of life (HRQoL); short-form health survey (SF-36)

Mesh:

Year:  2014        PMID: 25239925     DOI: 10.1177/0961203314551809

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  7 in total

1.  Length of exposure to antiphospholipid antibodies, rather than age, is a risk factor for thrombosis: a retrospective single-centre observational study.

Authors:  Iñigo Les; Naiara Parraza; Pilar Anaut; Saioa Eguiluz; Cristina Sánchez; María Enriqueta Preciado; Jesús Ángel Loza; Ander Andía
Journal:  Rheumatol Int       Date:  2017-11-10       Impact factor: 2.631

Review 2.  The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus.

Authors:  Ozan Ünlü; Stephane Zuily; Doruk Erkan
Journal:  Eur J Rheumatol       Date:  2015-12-29

3.  Diagnosis and treatment of patients with antiphospholipid syndrome: a mixed-method evaluation of care in The Netherlands.

Authors:  Mirthe J Klein Haneveld; Caro H C Lemmen; Tammo E Brunekreef; Marc Bijl; A J Gerard Jansen; Karina de Leeuw; Julia Spierings; Maarten Limper
Journal:  Rheumatol Adv Pract       Date:  2020-06-12

Review 4.  Organ Damage and Quality of Life in Antiphospholipid Syndrome.

Authors:  P Alba; J A Gómez-Puerta; M V Goycochea-Robles; M C Amigo
Journal:  Curr Rheumatol Rep       Date:  2016-02       Impact factor: 4.592

5.  Neuromyelitis optica spectrum disorder: Patient experience and quality of life.

Authors:  Janine Beekman; Aysha Keisler; Omar Pedraza; Masayuki Haramura; Athos Gianella-Borradori; Eliezer Katz; John N Ratchford; Gerard Barron; Lawrence J Cook; Jacinta M Behne; Terrence F Blaschke; Terry J Smith; Michael R Yeaman
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-06-20

6.  Fatigue in adults with primary antiphospholipid syndrome: findings from a mixed-methods study.

Authors:  Lindsay M Bearne; Julie Bieles; Sofia Georgopoulou; Josie Andrews; Amy Tully; Katrine Stolarchuk-Prowting; Tom Williamson; Beatriz Santana Suarez; Louise Nel; David D'Cruz; Heidi Lempp
Journal:  Lupus       Date:  2020-06-05       Impact factor: 2.911

7.  Examining the health-related quality of life using EQ-5D-5L in patients with four kinds of chronic diseases from specialist outpatient clinics in Hong Kong SAR, China.

Authors:  Richard Huan Xu; Annie Wai Ling Cheung; Eliza Lai-Yi Wong
Journal:  Patient Prefer Adherence       Date:  2017-09-12       Impact factor: 2.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.